Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | CA2 | P00918 | 4/20 | 0.34 |
| ▸ | CA4 | P22748 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11792981 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL28277555 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL1773954 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL437092 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL27281565 | 0.90 | ALDH1A1 (0.53) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL417312 | 0.90 | ALDH1A1 (0.53) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL10582055 | 0.87 | MEN1 (0.52) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL1830737 | 0.87 | ALDH1A1 (0.37) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL9509397 | 0.87 | ALDH1A1 (0.37) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL1774061 | 0.87 | ALDH1A1 (0.38) | ALDH1A1CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433086-B1 | ENERGETIC MATERIALS | TNO (NL) | 2026-05-06 | — | — | EP | claimed |
| US-20260115188-A1 | METHODS OF TREATING CENTERAL NERVOUS SYSTEM DISORDERS COMPRISING ADMINISTERING DEUTERATED LUMATEPERONE AND A NITRIC OXIDE DONOR | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-30 | — | — | US | claimed |
| US-20260110607-A1 | TRANSPORT AND DETECTION OF EXPLOSIVE SAMPLES WITH MINIMIZED FALSE POSITIVES | ALTI LLC (US) | 2026-04-23 | — | — | US | claimed |
| US-12590249-B2 | Etchant composition | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2026-03-31 | — | — | US | claimed |
| US-12517047-B2 | Transport and detection of explosive samples | ALTI LLC (US) | 2026-01-06 | — | — | US | claimed |
| US-12478623-B2 | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-11-25 | — | — | US | claimed |
| EP-4634138-A1 | NEW METHOD FOR SUSTAINABLE MANURE MANAGEMENT | DSM IP Assets B.V. (NL) | 2025-10-22 | — | — | EP | claimed |
| US-20250237601-A1 | TRANSPORT AND DETECTION OF EXPLOSIVE SAMPLES | ALTI LLC | 2025-07-24 | — | — | US | claimed |
| US-20250236569-A1 | Lead-free Ballistic Modifier for Rocket Motor Propellants | USA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2025-07-24 | — | — | US | claimed |
| US-20250011476-A1 | ARTICLES COMPRISING CROSSLINKED POLYMER NETWORK COMPRISING THIOETHER CROSSLINKS AND PROCESS OF MAKING AND USING SAME | US GOV AIR FORCE (US) | 2025-01-09 | — | — | US | claimed |
| US-4339288-A | Gas generating composition | Stang, Peter (US) | 1982-07-13 | — | — | US | claimed |
| US-4336085-A | MODIFYING THE DETONATION VELOCITY | WALKER FRANKLIN E | 1982-06-22 | — | — | US | claimed |
| US-4304614-A | AMMUNITION, DYNAMIC LASERS, FUSES, WELDING | WALKER FRANKLIN E | 1981-12-08 | — | — | US | claimed |
| EP-0030429-A2 | Fuels and a method of running an engine using such fuels | AECI LIMITED (ZA) | 1981-06-17 | — | — | EP | claimed |
| US-4243442-A | Pre-solution preparation of double base propellant binder | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1981-01-06 | — | — | US | claimed |
| US-4239561-A | NITRATE ESTERS AND CUPRIC RESORCYLATE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1980-12-16 | — | — | US | claimed |
| US-4092188-A | PLASTICIZED BINDER CONTAINING MONOPROPELLANT TO SMOOTH OUT BURNING RATE CURVE | LOVELACE ALAN M ACTING ADMINIS | 1978-05-30 | — | — | US | claimed |
| US-4051207-A | PROCESS FOR THE PRODUCTION OF PROPELLANT CHARGE POWDERS, ESPECIALLY NITROGUANIDINE POWDERS | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) | 1977-09-27 | — | — | US | claimed |
| US-4002514-A | DOUBLE BASE; NITRAMINE OXIDIZER; TRIAMINOGUANIDINIUM-AZIDE OR -HYDRAZINIUM DIAZIDE | THE DOW CHEMICAL COMPANY (US) | 1977-01-11 | — | — | US | claimed |
| US-3977922-A | NITRO COMPOUNDS IN THERMOSETTING RESINS | NIPPON OILS AND FATS COMPANY LIMITED (JA) | 1976-08-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590249-B2 | Etchant composition | ASIC1, NOS1, CA1 | ALDH1A1 2289/4885CA12 79/4885CA1 3/4885 |
| US-20260110607-A1 | TRANSPORT AND DETECTION OF EXPLOSIVE SAMPLES WITH MINIMIZED FALSE POSITIVES | TES, TNPO1, SLC2A1 | ALDH1A1 4406/4885CA12 2711/4885CA1 976/4885 |
| US-20260115188-A1 | METHODS OF TREATING CENTERAL NERVOUS SYSTEM DISORDERS COMPRISING ADMINISTERING DEUTERATED LUMATEPERONE AND A NITRIC OXIDE DONOR | HTR2C, DRD2, HTR2A | ALDH1A1 669/4885CA12 3720/4885CA1 3490/4885 |
| US-12478623-B2 | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor | HTR2A, HTR2C, HTR5A | ALDH1A1 436/4885CA12 3975/4885CA1 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.